CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach
Read-Out Expected Shortly
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.
You may also be interested in...
CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.